Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Rhea-AI Summary
Tevogen (Nasdaq: TVGN) announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in Atlanta March 16–20, 2026. Mr. Mehta will appear in two sessions on March 18 and March 19 covering agentic AI, adaptive data pipelines, governance, and enterprise readiness.
The sessions tie to Tevogen.AI’s work applying advanced machine learning to biomedical discovery, including its published international patent application (WO 2025/129197).
Positive
- None.
Negative
- None.
News Market Reaction – TVGN
On the day this news was published, TVGN gained 3.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TVGN fell about 7.35% while key biotech peers were mixed: KYTX -2.65%, IPHA -3.6%, NTHI -0.56%, but CRBU +4.79% and VTYX +0.07%, supporting a stock-specific move.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | AI platform update | Positive | -15.7% | Reported PredicTcell™ beta advances with larger datasets and stronger precision metrics. |
| Sep 25 | AI data expansion | Positive | +1.5% | Announced 100x PredicTcell™ beta data expansion and deeper Microsoft/Databricks integration. |
| Sep 10 | Conference appearance | Positive | -1.4% | CIO featured on Databricks AI panel discussing PredicTcell™ and scaling with partners. |
| Aug 11 | AI strategy letter | Positive | +8.8% | Stockholder letter highlighted AI expansion, strong capital position, and new platforms. |
| Aug 07 | AI funding grant | Positive | -8.8% | Received $1M non-dilutive funding within a $10M grant for Tevogen.AI development. |
AI-related updates often read positively but have produced mixed to negative next-day moves, with several selloffs following Tevogen.AI milestones.
Recent AI-tagged news for Tevogen centers on building the Tevogen.AI and PredicTcell™ platforms, expanding datasets to billions of records, and securing non-dilutive and grant funding, including $1 million from KRHP LLC within a $10 million grant. Partnerships with Microsoft and Databricks recur, along with communications highlighting capital strength and AI expansion. Against this backdrop, the FabCon 2026 speaking role underscores ongoing positioning of Tevogen as an AI-driven biotech innovator rather than introducing new clinical or financial data.
Historical Comparison
Past 5 AI-tagged updates saw an average move of -3.1%. This conference-focused AI news continues Tevogen.AI visibility efforts alongside prior platform and funding milestones.
AI-tagged history shows progression from launching PredicTcell™, to massive data expansion, to securing dedicated AI funding and repeated appearances at major AI and data conferences with Microsoft and Databricks.
Market Pulse Summary
This announcement spotlights Tevogen’s CIO presenting Tevogen.AI’s approach at FabCon 2026, reinforcing its positioning at the intersection of AI and immunology. Historical AI-tagged news emphasized PredicTcell™ data growth, patent activity, and non-dilutive funding. Investors may watch how these AI capabilities translate into clinical progress, revenue-generating partnerships, and funding beyond existing ATM and credit facilities, as well as how frequently positive AI updates coincide with subsequent share-price weakness.
Key Terms
immunologically active peptides medical
AI-generated analysis. Not financial advice.
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026), taking place March 16–20, 2026, in Atlanta, Georgia.
Mr. Mehta will participate in two sessions focused on the evolving intersection of data engineering and artificial intelligence:
- From Risk to Reward: Modernizing the Data Estate to Power Enterprise AI
Wednesday, March 18, 4:30PM – 5:05PM alongside Dipti Borkar, VP & GM OneLake & ISVs at Microsoft and Tripti Sethi, Data & AI Lead at Avanade. - Agentic Data Engineering on Microsoft Fabric: Building Adaptive Pipelines
Thursday, March 19, 4:15PM – 5:15PM alongside Nina Arora-Rowland, Data and AI Practice Lead at Avanade/Accenture, and Colin Pop, Senior Director, Analytics Architect at Avanade.
The sessions will explore how agentic AI is transforming modern data engineering, shifting pipelines from static, rules-based systems to adaptive, context-aware workflows. Topics will include emerging architectural patterns, real-world applications, and key considerations around governance, trust, and enterprise readiness as organizations adopt more autonomous data environments.
These themes align with Tevogen.AI’s broader efforts to apply advanced machine learning to biomedical discovery, including its published international patent application (WO 2025/129197), which outlines novel systems for predicting immunologically active peptides.
FabCon is Microsoft’s premier conference dedicated to its Fabric data platform, bringing together industry leaders, engineers, and innovators to explore the future of data and AI.
For more information or to connect with Mittul Mehta during the conference, please contact mittul.mehta@tevogen.com.
About Tevogen
Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.
Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.
Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.
Contact
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8feb8757-d993-45e3-a5da-3c4087c40abb
